Detail akcie Iovance Bthrptcs Rg online

Business Summary: Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Iovance Biotherapeutics Inc revenues increased 45% to $71.4M. Net loss decreased 32% to $79M. Revenues reflect Rest of world segment increase of 19% to $958K. Lower net loss reflects focused on developing and commercializing segment loss decrease of 33% to $81M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.36 to -$0.19.